A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.

ConditionAcne Vulgaris

Trial statusNot yet recruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorShanghai Huaota Biopharmaceutical Co., Ltd.

About this trial

The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.

Eligibility criteria

Qualifiers

None

Disqualifiers

1. Participants with known hypersensitivity to HB0043 or any of its excipients; 2. Those with facial skin or hair conditions, or with facial skin damage or abnormality that may interfere with clinical assessment.

Trial design

Treatments tested in this trial

HB0043
Placebo

Treatment groups

21 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Shanghai Huaota Biopharmaceutical Co., Ltd.

Lead sponsor

Dermatology Hospital affiliated to Shandong First Medical University

Collaborator

Source ClinicalTrials.gov